NCT06239623

ERK Inhibitor JSI-1187 in Advanced Solid Tumors

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JSI-1187 Capsule in the Treatment of Advanced Solid Tumors With MAPK Signaling Pathway Mutations

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: JS InnoPharm, LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

JSI-1187-101 phase 1 study

Detailed description

This study is a multicenter, open-label, dose-escalation and dose- expansion phase I clinical study. To investigate the safety, tolerability and PK characteristics of JSI-1187 capsule in Chinese patients with advanced solid tumors harboring MAPK signaling pathway mutations, and to evaluate the efficacy of JSI-1187 capsule in the treatment of advanced solid tumors harboring MAPK signaling pathway mutations.

Conditions

• Solid Tumor
• NSCLC
• Melanoma

Interventions

Type	Name	Description
DRUG	JSI-1187	Use ERK inhibitor JSI-1187 to treat solid tumor

Timeline

• Start date: 2022-04-02
• Primary completion: 2024-09-28
• Completion: 2024-12-30
• First posted: 2024-02-02
• Last updated: 2024-02-02

Locations

1 site across 1 country: China